Loading clinical trials...
Loading clinical trials...
A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers
Conditions
Interventions
Regorafenib (BAY73-4506) + rifampin
Locations
1
United States
Austin, Texas, United States
Start Date
March 1, 2011
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
December 19, 2014
NCT07169851
NCT00026884
NCT07159659
NCT07213804
NCT06662786
NCT07191730
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions